INOpulse Reduces Pulmonary Blood Pressure in PH With Sarcoidosis

INOpulse Reduces Pulmonary Blood Pressure in PH With Sarcoidosis

314619

INOpulse Reduces Pulmonary Blood Pressure in PH With Sarcoidosis

The use of the INOpulse combination drug-device therapy demonstrated a clinically meaningful reduction in pulmonary vascular resistance (PVR) — a measure of the internal resistance to blood flow within the lung arteries — in people with pulmonary hypertension (PH) associated with sarcoidosis (PH-Sarc). That’s according to top-line data from a proof-of-concept study evaluating increasing doses of INOpulse among PH patients with the immune system disorder. The Phase 2 clinical trial (NCT03727451) was sponsored by the…

You must be logged in to read/download the full post.